Commitments and Contingencies and Supply Source:	12 Months Ended
Feb. 29, 2024
Commitments and Contingencies and Supply Source:
Commitments and Contingencies and Supply Source:	7. Commitments and Contingencies and Supply Source: In the ordinary course of conducting business, the Company may be a party to legal proceedings and claims. As of February 29, 2024, the Company does not expect the final outcome of any such matters to have a material adverse effect on its financial position, results of operations, or cash flows. As described in Note 2, the Company entered a Royalty Agreement with Dr. Burzynski. Under that agreement, upon FDA approval, the Company is obligated to provide Dr. Burzynski the right to produce Antineoplaston products to treat up to 1,000 patients without paying any fees to the Company or the right to purchase Antineoplaston products to treat up to 1,000 patients at cost plus 10%. As such, Dr. Burzynski supplies all of the Antineoplaston products to the Company. No patients were treated during the years ended February 29, 2024 and February 28, 2023. Management estimates the current production facilities have the capacity to produce products to treat approximately 1,000 patients per year. There is space available at the current site to expand the facility for increased capacity if necessary. Supplies were purchased during the years ended February 29, 2024 and February 28, 2023, in the amount of $21 and $0, respectively. Dr. Burzynski has established additional vendors to supply these chemicals should there be a loss of these suppliers.

Commitments and Contingencies and Supply Source:

12 Months Ended

Feb. 29, 2024

Commitments and Contingencies and Supply Source:

Commitments and Contingencies and Supply Source:

7. Commitments and Contingencies and Supply Source:

In the ordinary course of conducting business, the Company may be a party to legal proceedings and claims. As of February 29, 2024, the Company does not expect the final outcome of any such matters to have a material adverse effect on its financial position, results of operations, or cash flows.

As described in Note 2, the Company entered a Royalty Agreement with Dr. Burzynski. Under that agreement, upon FDA approval, the Company is obligated to provide Dr. Burzynski the right to produce Antineoplaston products to treat up to 1,000 patients without paying any fees to the Company or the right to purchase Antineoplaston products to treat up to 1,000 patients at cost plus 10%. As such, Dr. Burzynski supplies all of the Antineoplaston products to the Company.

No patients were treated during the years ended February 29, 2024 and February 28, 2023. Management estimates the current production facilities have the capacity to produce products to treat approximately 1,000 patients per year. There is space available at the current site to expand the facility for increased capacity if necessary.

Supplies were purchased during the years ended February 29, 2024 and February 28, 2023, in the amount of $21 and $0, respectively. Dr. Burzynski has established additional vendors to supply these chemicals should there be a loss of these suppliers.